Sentence examples for treatment competed from inspiring English sources

There was little standardization of medical practice, and various sects — including homeopaths and allopaths, who took opposite approaches to treatment — competed for patients.

Secondly, the birds were exposed to a pair-wise dominance test, where two birds of the same sex, one from each treatment, competed for a common food resource which only one of them could access at the time.

Furthermore, the small sample size of the present study precluded separate analyses of treatment non-engagement (randomised but did not engage in treatment), early attrition (in this study defined as less than 15 weeks of treatment competed, the definition used in the main report of the trial [ 19] (p.6) and late attrition (in this study defined as completing 15 29 weeks of treatment).

One of the key objections to NHS mutuals is simply that doctors should be worrying about patients' needs and nothing else – particularly in hospitals, where so many critical (and expensive) areas of treatment compete for resources.

23 This is likely to be the result of a lack of awareness and knowledge, lack of appropriate local services, long waiting lists for treatment, competing family time commitments and a paucity of trained professionals.

Sanofi, based in Paris, is seeking new sources of revenue before the Plavix and Lovenox anticlot treatments compete with cheaper copies, starting in 2011.

However, since none of these companies develops or sells its own catheter products for vascular access in extracorporeal treatments, competing interests are unlikely for either the authors or the companies.

Amgen shares climbed 3.1 percent to $89.55, after a rival, Affymax, issued a voluntary recall of its only drug, an anemia treatment that competed with Amgen's top-selling drug, Epogen.

Network meta-analysis (NMA) allows for the comparison of multiple treatments in a comprehensive analysis and the determination of the best treatment among several competing treatments, including those that have never been compared in a head-to-head study.

In radiation therapy, the treatment responses compete with adverse effects, and monitoring the radiation sequelae and modifying treatment planning adaptively could improve the therapeutic benefit.

Despite longer mean follow-up in the BRACE treatment arm, competing risks models for both the time to first relapse and treatment discontinuation confirmed that this difference did not significantly influence the estimated HRs. Forty-one (4.7%) of the 869 matched patients who switched to natalizumab tested positive for anti-JCV antibodies at least once during the follow-up period.